Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Eluxadoline is a small molecule medication used to treat irritable bowel syndrome with diarrhea (IBS-D) in adults. It acts as a mixed mu-opioid receptor agonist and kappa-opioid receptor agonist, and as a delta-opioid receptor antagonist. Its primary mechanism involves reducing intestinal contractility and normalizing stress-induced acceleration of upper gastrointestinal transit. This results in decreased bowel activity and improved symptoms of abdominal pain and diarrhea[2][10][7]. Eluxadoline is available only by prescription.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on eluxadoline.